Page 15 - Adjunct News Today : Breaking News, Live Updates & Top Stories | Vimarsana

CCAD faculty say they want to unionize to have a bigger voice in academic decision making and to improve working conditions for adjunct faculty.

>> jacqui: almost had a serious issue with wagner. prigozhin is spotted in st. petersburg. he is supposed continue belarus. >> i think what happened, he's a favorite of putin. and what's happening, where is another general, he has not been seen. and what prigozhin said he is concerned about the russian generals and the secretary of defense shoigu, not pushing the fight where it should be fought. i think he's pretty well protected. plus wagner is probably one of the most capable forces the russians have. they are a paramilitary force, which is an adjunct to the russian military and i think that...

Of attention for battle field successes in ukraine but it is not like the wagner group is fighting as an independent force there. prigozhin's wagner mercenaries are basically a private augmentation, adjunct to the russian military. they rely on russian military infrastructure. they can't operate a whole war there on their own. the russian military has to be there, too. but that dynamic has created some friction. since the ukraine war started and russia's invasion of ukraine has gone so poorly from day one, prigozhin has taken on this sort of unsettling new role in russian politics both for put...

It is not like the wagner group is fighting as an independent force there. prigozhin's wagner mercenaries are basically a private augmentation, adjunct to the russian military. they rely on russian military infrastructure. they can't operate a whole war there on their own. the russian military has to be there, too. but that dynamic has created some friction. since the ukraine war started and russia's invasion of ukraine has gone so poorly from day one, prigozhin has taken on this sort of unsettling new role in russian politics both for putin and for everybody else. he has essentially taken cre...

- Met Primary Endpoint with 63.4% Median Reduction in LDL-C (p - 87.1% of Patients Treated with Combination of Obicetrapib and Ezetimibe Met Guideline-Recommended LDL-C Goal of - New Data Demonstrate